News | Left Atrial Appendage (LAA) Occluders | July 07, 2016

AtriCure Announces First Patient Enrolled in FROST Cryoanalgesia Study

FROST will evaluate cryoablation of peripheral nerves for the temporary management of post-operative pain with cryoICE probe

AtriCure, FROST cryoanalgesia study, William Beaumont Hospital Michigan, cryoICE system

July 7, 2016 — AtriCure Inc. announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, Mich. This company-sponsored trial will evaluate intraoperative cryoanalgesia therapy using cryoablation in conjunction with standard of care (SOC) pain management compared to SOC alone.

The design of the trial is a prospective, 3:1 randomized trial including a total of up to 100 patients. The randomization will include up to 75 patients in the treatment arm (intraoperative cryoablation with AtriCure’s cryoICE system plus SOC), and up to 25 patients in the control arm (SOC alone). The study will include patients undergoing unilateral thoracotomy cardiac procedures and will evaluate pain scores and lung function recovery during hospital stay.

The primary objective of the study is to demonstrate that intraoperative intercostal cryoanalgesia in conjunction with SOC provides improved analgesic efficacy and faster, more complete recovery in patients undergoing unilateral thoracotomy cardiac procedures as compared to current SOC. Additional endpoints, such as ICU length of stay, total hospital length of stay, opioid consumption and long-term neurologic recovery will be gathered.

“In my experience, cryoanalgesia appears to result in improved pain management,” said Steven F. Bolling, M.D., professor of cardiac surgery at University of Michigan Medical Center. “Perhaps more importantly, patients seem to extubate sooner and seem to be ready for an earlier discharge. FROST will seek to confirm this effect at multiple cardiac surgery institutions.”

“I have continued to see the benefits of cryoanalgesia therapies in conjunction with minimally invasive mitral valve surgery,” stated Francis Shannon, M.D., cardiothoracic surgeon, Beaumont Health System. “The benefit for patients is quite significant, and I look forward to developing further evidence through participation in the FROST study.”

Participating centers in the study are the William Beaumont Hospital and the University of Michigan Medical Center, as well as Cleveland Clinic Foundation. The coordinating investigators for the FROST study are Shannon and Wei Lau, M.D., at William Beaumont Hospital. Andrea Trescot, M.D., past president of the American Society of Interventional Pain Physicians, is serving as scientific advisor for this trial.

“Today’s pain management options offer relief while patients are hospitalized, but do little to address pain post-discharge,” said Lau, professor of anesthesiology at Oakland University William Beaumont School of Medicine. “We have seen cryoanalgesia control pain and improve recovery post-operatively.”

For more information: www.atricure.com

Related Content

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation.

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation. The technology allows different energies to be used for each electrode to prevent damage to the esophagus or other underlying critical structures. 

Feature | Atrial Fibrillation | January 15, 2018 | Dave Fornell
The development of atrial fibrillation (AFib or AF) ablation technologies over the past 20 years has been a constant
Heart Rhythm Society Partners With WebMD Education to Increase Atrial Fibrillation Awareness
News | Atrial Fibrillation | January 02, 2018
The Heart Rhythm Society (HRS), in partnership with WebMD Education, announced in December the launch of a free, online...
The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time.

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time. It was the first of a new generation of high-density mapping systems to be introduced.

Feature | Atrial Fibrillation | December 18, 2017 | Kenneth Stein, M.D. FACC FHRS
When I began practicing as an electrophysiologist in 1994, the dream of successfully using cardiac catheter ablation
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.

 

 

Feature | Atrial Fibrillation | November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation | November 02, 2017
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the B
UNC School of Medicine Receives $1.7 Million for Atrial Fibrillation Program Streamlining Patient Care
News | Atrial Fibrillation | October 23, 2017
October 23, 2017 — University of North Carolina (UNC) School of Medicine cardiologist Anil Gehi, M.D., will use a $1.
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Overlay Init